Results 21 to 30 of about 311 (111)

Once-Weekly Somatrogon in Pediatric Growth Hormone Deficiency: Real-World Efficacy, Safety, and Quality-of-Life Findings [PDF]

JCRPE
Objective: To report real-world 6- and 12-month outcomes in children with growth hormone deficiency (GHD) treated with somatrogon or somatropin, including those who transitioned from somatropin to somatrogon.
Kübra Şen Küçük, Sebla Güneş, Mustafa Dinçer, Sercan Öztürk, Tolga Ünüvar, Ahmet Anık   +5 more
doaj   +2 more sources

Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis [PDF]

Pharmacological Research, 2023
We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the treatment of growth hormone deficiency (GHD) in children. Systematic searches
Chiara Mameli, Massimiliano Orso, Valeria Calcaterra, Malgorzata Gabriela Wasniewska, Tommaso Aversa, Simona Granato, Pietro Bruschini, Liliana Guadagni, Daniela d’Angela, Federico Spandonaro, Barbara Polistena, Gianvincenzo Zuccotti   +11 more
doaj   +2 more sources

Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations" [PDF]

Annals of Pediatric Endocrinology & Metabolism
Yoo-Mi Kim
doaj   +4 more sources

Influence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study [PDF]

J Endocrinol Invest
Introduction/purpose Long‑acting growth hormone (LAGH) formulations have emerged to address poor adherence to daily recombinant human growth hormone (rhGH), offering reduced injection frequency and comparable efficacy.
Valeria Citterio, Camilla Mazzi, Claudia Giavoli, Giulia Rodari, Valentina Collini, Aurora Pedroli, Giovanna Mantovani, Eriselda Profka   +7 more
core   +2 more sources

Real-World Efficacy of Weekly Somatrogon on Growth and Bone Health in Pediatric Growth Hormone Deficiency: A 12-Month Retrospective Cohort Study [PDF]

JCRPE
Objective: Growth hormone deficiency (GHD) in children results in short stature and impaired bone health. While daily growth hormone (GH) injections are effective, they are associated with adherence challenges.
Mohammad Hosny Awad, Reham Ghanim, Rania Eladl, Zulf Mughal, Manal Mustafa   +4 more
doaj   +2 more sources

Detection of the GH analogue somatrogon in doping control urine samples by means of LC-HRMS/MS [PDF]

Scientific Reports
Somatrogon is a synthetic growth hormone (GH) analog, whose misuse in sports is prohibited at all times. As analytical approaches complementary to existing immunological GH detection methods were considered beneficial for its detection in doping control ...
Katja Walpurgis, Andreas Thomas, Alexandra Rauer, Bettina Majer, Mitsuhiko Sato, Masato Okano, Maneera Al-Jaber, Wadha Abushareeda, Cristian-Gabriel Arsene, Hans Geyer, Mario Thevis   +10 more
doaj   +2 more sources

Detection of the GH analog somatrogon in sports drug testing: Immunological approaches and LC‐HRMS/MS [PDF]

Drug Testing and Analysis, Volume 17, Issue 5, Page 634-646, May 2025.
The detectability of the GH analog somatrogon with approved doping control immunoassays for hGH and hCG was evaluated and a both sensitive and specific qualitative detection assay employing affinity purification, tryptic digestion, and LC‐HRMS/MS was developed to confirm the presence of the drug in suspicious serum samples. Abstract Due to the presumed
Katja Walpurgis, Andreas Thomas, Mitsuhiko Sato, Masato Okano, Hans Geyer, Mario Thevis   +5 more
wiley   +2 more sources

Comparison of efficacy and safety between long-acting growth hormone and short-acting growth hormone in isolated growth hormone deficiency: a systematic review and meta-analysis of 16 randomized controlled trials involving 2,435 pediatric patients [PDF]

Frontiers in Pediatrics
ObjectiveTo comprehensively compare the efficacy and safety of long-acting human growth hormone (LAGH) preparations with conventional short-acting daily growth hormone (SA-GH) in children with isolated growth hormone deficiency (GHD), and explore ...
Zhen-Zhen Shen, Yun Huang, Li-Li Wu, Jian-Su Zhang, Xiao-Xia Zhang   +4 more
doaj   +2 more sources

Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon

CPT: Pharmacometrics & Systems Pharmacology
AbstractFully Bayesian approaches are not commonly implemented for population pharmacokinetic (PK) modeling. In this paper, we evaluate the use of Stan with R and Torsten for population PK modeling of somatrogon, a recombinant long‐acting growth hormone approved for the treatment of growth hormone deficiency.
Yuchen Wang, Xinyi Pei, Tao Niu, Joan Korth‐Bradley, Luke Fostvedt   +4 more
openaire   +3 more sources

Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study [PDF]

Pituitary
PURPOSE: This study assessed the efficacy and safety of once-weekly somatrogon, a long-acting growth hormone, in adults with growth hormone deficiency (aGHD). METHODS: A phase 3 randomized, double-blind, placebo-controlled study consisted of a 26-week double-blind period (Period 1), a 26-week open-label extension (OLE; Period 2), and a multi-year OLE ...
Fleseriu, Maria, Biller, Beverly M. K., Webb, Susan M., Strasburger, Christian J., Georgescu, Carmen E., Bidlingmaier, Martin, Wang, Christina, Baciu, Ionela, Casanueva, Felipe F., Gilis-Januszewska, Aleksandra, Hart, Gili, Manners, Allison, Choe, John, Bar-Ilan, Ahuva, Carlsson, Martin, Torre, Daria La, Taylor, Carrie Turich, Yuen, Kevin C.J.   +17 more
openaire   +5 more sources